Please assess the completion status of the following clinical trial:

Trial Title: Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria :~* Participant is healthy, as determined by medical history and physical examination.~* Participant is at least 13 years of age but not yet 22 years of age at time of enrollment.~* For the Menactra® and Menomune® groups, participant received one dose of Menactra® or Menomune® in MTA02 trial and completed trial (2 blood samples, contacted for Month 6 safety follow up).~* For the Control group, participant has no previous history of any meningococcal vaccination.~* If \< 18 years of age, participant has signed Institutional Review Board (IRB) approved informed assent form and his/her parent/legal guardian has signed an IRB-approved informed consent form.~* If ≥ 18 years of age, participant has signed an IRB-approved informed consent form.~* Able to provide vaccination log.~Exclusion Criteria :~* Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc).~* Known or suspected impairment of immunologic function.~* Acute medical illness with or without fever within the last 72 hours or an oral temperature ≥ 100.4ºF (≥ 38.0ºC) at the time of inclusion.~* For the Menactra® and Menomune® groups, history of documented invasive meningococcal disease or previous meningococcal vaccination with the exception of meningococcal vaccination given as part of MTA02 trial.~* For the Control group, history of documented invasive meningococcal disease or previous meningococcal vaccination.~* Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.~* Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn.~* Received any vaccine in the 14-day period prior to study vaccination, or scheduled to receive any vaccination during the 14-day period after study vaccination.~* Suspected or known hypersensitivity to any of the vaccine components.~* Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures.~* In females, a positive or equivocal urine pregnancy test at the time of vaccination.~* Enrolled in another clinical trial.~* Any condition, which, in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the vaccine.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Menactra® Group (Type: EXPERIMENTAL): Received Menactra® vaccine in Study MTA02
- Menomune® Group (Type: EXPERIMENTAL): Received Menomune® vaccine in Study MTA02
- Control Group (Type: EXPERIMENTAL): Meningococcal vaccine-naïve Control Group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete